CStone Pharmaceuticals announced on the Hong Kong Stock Exchange on September 15th that CS2015 (OX40L/TSLP bispecific antibody), one of its pipeline products in the autoimmunity and inflammation field, has been selected for presentation at the 2025 American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. The meeting will be held in Orlando, USA from November 6th to 10th. CS2015 is a potential first-in-class/best-in-class bispecific antibody that simultaneously targets OX40L and TSLP. By dually inhibiting key regulators of Th2-mediated inflammatory responses, it offers a novel therapeutic strategy for type 2 inflammatory diseases such as atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD).